Showing results (1291-1300 of 3,105) with videos related to
Sort By:
Pageof 311
Drug Safety|November 2, 2007
Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsisDaniel De BackerDrug Safety|August 19, 2008
RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomideCarmen P Castaneda, Jerome B Zeldis, John Freeman, et al.Drug Safety|August 19, 2008
Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysisEleanor B Schwarz, Myla E Moretti, Smita Nayak, et al.Drug Safety|August 19, 2008
Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitalsYurdaguel Zopf, Christina Rabe, Antje Neubert, et al.Drug Safety|November 27, 2007
Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidanceRashmi R ShahDrug Safety|November 27, 2007
Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES)Manfred Hauben, Lester Reich, Charles M Gerrits, et al.Drug Safety|November 26, 2008
Long-term consequences of drugs on the paediatric cardiovascular systemElizabeth Hausner, Monica L Fiszman, Joseph Hanig, et al.Drug Safety|November 26, 2008
Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reportingMarco Tuccori, Francesco Lapi, Arianna Testi, et al.Drug Safety|November 26, 2008
Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the NetherlandsPetal A H M Wijnen, Marjolein Drent, Patty J Nelemans, et al.Drug Safety|November 26, 2008
Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the NetherlandsHilbert S de Vries, Martijn G H van Oijen, Dirk J de JongPageof 311